Kura Oncology, Inc. (NASDAQ:KURA)
Industry: Biotechnology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Current Quote*
Last: $9.930
Change: 0.000
Book: $1.637
Volume: 1,613,478

As Of: 06/18 16:15 ET
*Quotes delayed by 20min.

Graphs for KURA


3 Month Graph


6 Month Graph


1 Year Graph